Plasma exchange therapy for the treatment of Escherichia coli O-157 associated hemolytic uremic syndrome.
Plasma exchange (PE) therapy was administered to three patients with Escherichia coli O-157 associated hemolytic uremic syndrome (HUS) in early phase. Following several PE treatments, all cases completely recovered without any apparent complications. The usefulness of PE therapy in removing microbial fragments and inflammatory cytokines was evaluated. The peptidoglycan (PG) level, interleukin-1 receptor antagonist (IL-1Ra) were higher in HUS patients starting PE therapy than in patients who had received several sessions of PE therapy. PE therapy was an effective early phase treatment for Escherichia coli O-157 associated HUS.
Nakatani
Tatsuya
T
Department of Urology and Division of Artificial Kidney, Osaka City University Medical School, Osaka City, Japan. nakatani@msic.med.osaka-cu.ac.jp
Tsuchida
Kenji
K
Yoshimura
Rikio
R
Sugimura
Kazunobu
K
Takemoto
Yoshiaki
Y
D002648:Child; D004731:Endotoxins / Q000097:blood; D004927:Escherichia coli Infections / Q000097:blood / Q000382:microbiology / Q000628:therapy*; D019453:Escherichia coli O157; D005260:Female; D005936:Glucans / Q000097:blood; D006463:Hemolytic-Uremic Syndrome / Q000097:blood / Q000382:microbiology / Q000628:therapy*; D006801:Humans; D053590:Interleukin 1 Receptor Antagonist Protein; D007375:Interleukin-1 / Q000097:blood; D010457:Peptidoglycan / Q000097:blood; D010951:Plasma Exchange; D022603:Shiga Toxins / Q000097:blood; D012795:Sialoglycoproteins / Q000097:blood
D004731:Endotoxins; D005936:Glucans; C507763:IL1RN protein, human; D053590:Interleukin 1 Receptor Antagonist Protein; D007375:Interleukin-1; D010457:Peptidoglycan; D022603:Shiga Toxins; D012795:Sialoglycoproteins; C044101:endotoxin, Escherichia coli